TRCT
BMY icon

Tower Research Capital (TRC)’s Bristol-Myers Squibb BMY Stock Holding History

Tower Research Capital (TRC)’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Sell
28,860
-29,240
-50% -$1.7M 0.05% 379
2025
Q4 		$3.13M Sell
58,100
-17,426
-23% -$838K 0.08% 229
2025
Q3 		$3.41M Sell
75,526
-78,432
-51% -$3.66M 0.09% 182
2025
Q2 		$7.13M Buy
153,958
+94,647
+160% +$4.65M 0.19% 86
2025
Q1 		$3.62M Sell
59,311
-64,688
-52% -$3.77M 0.11% 156
2024
Q4 		$7.01M Buy
123,999
+58,625
+90% +$3.28M 0.14% 109
2024
Q3 		$3.38M Sell
65,374
-133,372
-67% -$6.26M 0.09% 154
2024
Q2 		$8.25M Buy
198,746
+166,996
+526% +$7.47M 0.14% 109
2024
Q1 		$1.72M Sell
31,750
-246,564
-89% -$12.6M 0.04% 332
2023
Q4 		$14.3M Buy
278,314
+211,949
+319% +$11.1M 0.18% 101
2023
Q3 		$3.85M Buy
66,365
+12,577
+23% +$771K 0.12% 144
2023
Q2 		$3.44M Buy
53,788
+19,389
+56% +$1.3M 0.11% 114
2023
Q1 		$2.38M Sell
34,399
-2,098
-6% -$148K 0.08% 165
2022
Q4 		$2.63M Sell
36,497
-140,803
-79% -$10.6M 0.11% 133
2022
Q3 		$12.6M Buy
177,300
+57,676
+48% +$4.18M 0.2% 82
2022
Q2 		$9.21M Sell
119,624
-160,838
-57% -$12.2M 0.21% 73
2022
Q1 		$20.5M Buy
280,462
+148,020
+112% +$9.94M 0.2% 95
2021
Q4 		$8.26M Buy
132,442
+78,839
+147% +$4.62M 0.14% 109
2021
Q3 		$3.17M Sell
53,603
-9,069
-14% -$597K 0.08% 171
2021
Q2 		$4.19M Sell
62,672
-175,736
-74% -$11.5M 0.11% 125
2021
Q1 		$15.1M Buy
238,408
+188,738
+380% +$11.7M 0.25% 70
2020
Q4 		$3.08M Buy
49,670
+10,205
+26% +$628K 0.09% 139
2020
Q3 		$2.38M Buy
39,465
+12,662
+47% +$762K 0.03% 290
2020
Q2 		$1.58M Buy
26,803
+23,054
+615% +$1.38M 0.06% 306
2020
Q1 		$209K Buy
+3,749
New +$229K 0.01% 730
2019
Q4 		– Sell
-29,283
Closed -$1.49M – 3565
2019
Q3 		$1.49M Buy
+29,283
New +$1.38M 0.1% 175
2019
Q2 		– Sell
-24,251
Closed -$1.16M – 3683
2019
Q1 		$1.16M Sell
24,251
-1,817
-7% -$90.5K 0.07% 232
2018
Q4 		$1.35M Buy
26,068
+20,135
+339% +$1.08M 0.1% 204
2018
Q3 		$369K Sell
5,933
-31,035
-84% -$1.84M 0.03% 648
2018
Q2 		$2.05M Buy
36,968
+34,568
+1,440% +$1.87M 0.11% 165
2018
Q1 		$152K Sell
2,400
-20,694
-90% -$1.33M 0.01% 1017
2017
Q4 		$1.42M Buy
+23,094
New +$1.44M 0.18% 122
2017
Q3 		– Sell
-5,205
Closed -$290K – 3784
2017
Q2 		$290K Buy
5,205
+1,907
+58% +$104K 0.03% 277
2017
Q1 		$179K Sell
3,298
-23,823
-88% -$1.31M 0.02% 305
2016
Q4 		$1.58M Buy
27,121
+23,706
+694% +$1.3M 0.17% 122
2016
Q3 		$184K Sell
3,415
-25,582
-88% -$1.64M 0.02% 523
2016
Q2 		$2.13M Buy
28,997
+28,273
+3,905% +$2M 0.2% 83
2016
Q1 		$46K Buy
724
+549
+314% +$34.6K 0.01% 817
2015
Q4 		$12K Buy
+175
New +$11.6K ﹤0.01% 1869
2015
Q2 		– Sell
-7,280
Closed -$480K – 4397
2015
Q1 		$470K Buy
+7,280
New +$456K 0.06% 182
2014
Q4 		– Sell
-16,591
Closed -$849K – 4031
2014
Q3 		$849K Buy
16,591
+16,495
+17,182% +$824K 0.1% 184
2014
Q2 		$5K Sell
96
-2,717
-97% -$134K ﹤0.01% 2831
2014
Q1 		$146K Buy
+2,813
New +$150K 0.02% 521
2013
Q4 		– Sell
-941
Closed -$44K – 4467
2013
Q3 		$44K Buy
941
+913
+3,261% +$40.1K ﹤0.01% 2017
2013
Q2 		$1K Buy
+28
New +$1.22K ﹤0.01% 3647

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tower Research Capital (TRC)'s BMY Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Bristol-Myers Squibb (BMY) stake by 50% in Q1 2026, selling an estimated $1.7M and leaving 28,860 shares worth $1.75M. The position accounts for 0.05% of the portfolio, ranked #379.

Tower Research Capital (TRC) first reported a position in BMY in Q2 2013 and has held it in 45 quarters since. The position peaked at $20.5M in Q1 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Tower Research Capital (TRC) held 28,860 shares of Bristol-Myers Squibb worth $1.75M as of Q1 2026.
  • Tower Research Capital (TRC) sold 29,240 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.7M.
  • Bristol-Myers Squibb made up 0.05% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #379 holding.
  • Tower Research Capital (TRC) first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 45 quarters since.
  • Tower Research Capital (TRC)'s Bristol-Myers Squibb position peaked at $20.5M in Q1 2022.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.